Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00211393 · ClinicalTrials.gov registry record · Phase 2
A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole
A Phase 2 study, sponsored by Manhattan Eye, Ear & Throat Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00211393 is a Phase 2 study that has completed, run by Manhattan Eye, Ear & Throat Hospital. The registered enrollment target is 5 participants.
The verdict
NCT00211393, a Phase 2 study, has completed, sponsored by Manhattan Eye, Ear & Throat Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect of an adrenocorticoid antagonist (ketoconazole), 600 mg per day for 4 weeks, in the treatment of patients with central serous chorioretinopathy (CSC).
Interventions
- DRUG ketoconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2005-05 |
| Est. Completion | 2008-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00211393
The ClinicalTrials.gov registry entry for NCT00211393 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Manhattan Eye, Ear & Throat Hospital, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ketoconazole is the first listed.
NCT00211393 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00211393 about?
NCT00211393 is a clinical study titled "A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole". The purpose of this study is to determine the effect of an adrenocorticoid antagonist (ketoconazole), 600 mg per day for 4 weeks, in the treatment of patients with central serous chorioretinopathy (CSC).
What is the current status of trial NCT00211393?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2005-05. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00211393?
The interventions under investigation include: ketoconazole (DRUG).
Who is sponsoring clinical trial NCT00211393?
This trial is sponsored by Manhattan Eye, Ear & Throat Hospital, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.